Skip to Content
Merck
CN
  • A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome.

A multi-omics based anti-inflammatory immune signature characterizes long COVID-19 syndrome.

iScience (2022-12-13)
Johannes J Kovarik, Andrea Bileck, Gerhard Hagn, Samuel M Meier-Menches, Tobias Frey, Anna Kaempf, Marlene Hollenstein, Tarik Shoumariyeh, Lukas Skos, Birgit Reiter, Marlene C Gerner, Andreas Spannbauer, Ena Hasimbegovic, Doreen Schmidl, Gerhard Garhöfer, Mariann Gyöngyösi, Klaus G Schmetterer, Christopher Gerner
ABSTRACT

To investigate long COVID-19 syndrome (LCS) pathophysiology, we performed an exploratory study with blood plasma derived from three groups: 1) healthy vaccinated individuals without SARS-CoV-2 exposure; 2) asymptomatic recovered patients at least three months after SARS-CoV-2 infection and; 3) symptomatic patients at least 3 months after SARS-CoV-2 infection with chronic fatigue syndrome or similar symptoms, here designated as patients with long COVID-19 syndrome (LCS). Multiplex cytokine profiling indicated slightly elevated pro-inflammatory cytokine levels in recovered individuals in contrast to patients with LCS. Plasma proteomics demonstrated low levels of acute phase proteins and macrophage-derived secreted proteins in LCS. High levels of anti-inflammatory oxylipins including omega-3 fatty acids in LCS were detected by eicosadomics, whereas targeted metabolic profiling indicated high levels of anti-inflammatory osmolytes taurine and hypaphorine, but low amino acid and triglyceride levels and deregulated acylcarnitines. A model considering alternatively polarized macrophages as a major contributor to these molecular alterations is presented.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-phospho-mTOR (Thr2446) Antibody, Upstate®, from rabbit